Welcome to our dedicated page for Maze Therapeutics SEC filings (Ticker: MAZE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Maze Therapeutics, Inc. (Nasdaq: MAZE) SEC filings page brings together the company’s public regulatory disclosures, offering a detailed view of how this clinical-stage biopharmaceutical company reports its activities to U.S. regulators. Maze focuses on small molecule precision medicines for kidney and metabolic diseases, and its filings provide context on both its scientific programs and its capital markets activity.
Maze’s filings include current reports on Form 8-K, which the company uses to announce material events such as quarterly financial results, leadership changes, and financing transactions. For example, Maze has filed 8-Ks to furnish press releases on second and third quarter financial results, to disclose an oversubscribed private placement of common stock and pre-funded warrants, and to document the appointments of a new chief financial officer and a new chairman of the board.
Investors can also review registration statements, such as the company’s Form S-1, which describes Maze’s business, risk factors, and the resale of shares issued in its 2025 private placement. The S-1 outlines Maze’s focus on human genetics, its Compass platform, and its lead programs MZE829 and MZE782, while also confirming its status as an emerging growth company and smaller reporting company.
Through Stock Titan, these filings are updated in near real time from the SEC’s EDGAR system, and AI-powered summaries help explain the key points of lengthy documents. Users can quickly understand what a particular 8-K, S-1, or other filing means for the company without reading every page. Where applicable, filings related to equity financings, registration rights, and governance changes are highlighted so investors can track dilution, board composition, and executive appointments.
For MAZE, monitoring SEC filings is especially relevant for understanding clinical development disclosures, financing capacity, and risk factors associated with its kidney and metabolic disease programs. This page serves as a central resource for reviewing those official documents alongside concise AI-generated explanations.
Alphabet Inc. and its GV investment affiliates report a minority stake in Maze Therapeutics. As of December 31, 2025, they may be deemed to beneficially own 1,388,583 shares of Maze common stock, representing 2.9% of shares outstanding.
The holdings are split between GV 2019, L.P. with 784,019 shares (1.6%) and GV 2023, L.P. with 604,564 shares (1.3%), with control cascading through GV general partners to Alphabet subsidiaries and ultimately Alphabet Inc. The filing confirms ownership of 5% or less of the class.
Maze Therapeutics, Inc. has filed an automatic shelf registration and established an at-the-market offering program to sell up to $200,000,000 of common stock through Jefferies LLC as sales agent. Shares will be sold from time to time at prevailing market prices, with Jefferies earning up to 3% in commissions.
The company plans to use any net proceeds for general corporate purposes, including research and development, working capital, capital spending, and potential acquisitions. Maze is a clinical-stage biopharmaceutical company focused on precision medicines for kidney and metabolic diseases, and it had 48,076,885 common shares outstanding as of September 30, 2025.
Maze Therapeutics, Inc. entered into a senior secured term loan agreement with Hercules Capital providing up to $200.0 million in potential borrowing capacity. An initial $40.0 million tranche was funded at closing, generating approximately $38.4 million of net proceeds after fees.
The facility matures on February 1, 2031, carries a floating interest rate based on the Wall Street Journal prime rate with floors between 7.95% and 9.25%, and offers an interest-only period of up to 48 months, or up to 60 months if specified milestones are met. Repayments trigger an exit fee of 3.95% to 6.45% of principal, and early prepayments can incur premiums of up to 3.00% within the first 12 months.
The loan is secured by a first lien on substantially all of Maze’s assets and includes customary representations, covenants, financial tests, and events of default, including minimum unrestricted cash requirements tied to market capitalization and outstanding loan balances. Concurrently, the company terminated its prior Loan and Security Agreement with Banc of California and released that lender’s security interest in its assets.
Maze Therapeutics President, R&D & CMO Harold Bernstein reported an automatic stock transaction under a Rule 10b5-1 trading plan. On February 2, 2026, he exercised a stock option for 15,000 shares of common stock at an exercise price of $10.42 per share.
On the same date, he sold a total of 15,000 common shares in several market transactions at weighted average prices of $44.205, $45.8891, $46.3732 and $47.23 per share, with actual sale prices ranging from $44.15 to $47.17 per share. After these sales, he reported 0 shares of common stock directly owned and 297,407 stock options remaining, linked to an award that began vesting on October 3, 2023.
Maze Therapeutics SVP Finance Amy Bachrodt reported option exercises and share sales. On February 2, 2026, she exercised stock options for 4,844 and 156 shares of common stock at an exercise price of $10.42 per share.
That same day she sold 200 shares at $44.15, 4,064 shares at a weighted average price of $46.0305, and 736 shares at a weighted average price of $46.6323. The sales were effected under a Rule 10b5-1 trading plan. After these transactions, she directly owned 12,965 common shares, along with vested and vesting stock options.
Maze Therapeutics, Inc. executive Atul Dandekar reported an option exercise and planned share sales. On January 29, 2026, he exercised a stock option for 7,500 shares of common stock at $10.42 per share, from a fully vested award. The same day, he sold 7,500 common shares in three trades: 1,200 shares at $43.1844, 3,500 shares at $44.0419, and 2,800 shares at $45.008, all under a pre-established Rule 10b5-1 trading plan. After these transactions, he reported owning 10,503 shares of common stock and 66,643 stock options, all held directly.
Maze Therapeutics SVP of Finance Amy Bachrodt reported option exercises and a stock sale. On January 22, 2026, she exercised stock options to acquire 2,497 and 2,503 shares of common stock at an exercise price of $10.42 per share. On the same date, she sold 5,000 shares of common stock at a weighted average price of $45.5224 per share under a pre-arranged Rule 10b5-1 trading plan. Following these transactions, she directly held 12,965 shares of Maze Therapeutics common stock and retained stock options covering 486 and 7,869 shares, subject to monthly vesting schedules.
MAZE insider Sekar Kathiresan has filed a notice to sell 29,772 shares of common stock under Rule 144. The planned sale, with an aggregate market value of $1,210,937.40, is to be executed through Morgan Stanley Smith Barney LLC on or about January 16, 2026 on the NASDAQ market. The filing notes that 48,119,444 shares of the issuer’s common stock were outstanding.
The 29,772 shares to be sold were acquired on January 16, 2026 via a stock option exercise from the issuer, paid for in cash. Over the prior three months, Kathiresan sold additional common shares, including 10,000 shares on December 4, 2025 for gross proceeds of $425,423.00 and 27,500 shares on November 21, 2025 for gross proceeds of $984,588.00.
Maze Therapeutics executive Harold Bernstein, President, R&D & CMO, reported an option exercise and related share sale. On January 7, 2026, he exercised a stock option for 25,156 shares of common stock at an exercise price of $10.42 per share, converting a previously held derivative position into common stock.
On the same day, he sold the same 25,156 shares of common stock at a weighted average price of $40.2011 per share under a Rule 10b5-1 trading plan adopted on September 29, 2025, leaving him with 0 directly held common shares and 312,407 stock options outstanding. The sale price reflects multiple transactions between $40.00 and $40.55 per share.
Maze Therapeutics director Catherine A. Sohn reported a series of stock option exercises and related common share sales. On January 6, 2026, she exercised 2,493 stock options at an exercise price of $10.42 per share and sold 2,493 common shares at a weighted average price of $38.616 per share, leaving no common shares directly owned.
On January 7, 2026, she exercised additional options for 20,744, 2,895, and 3,281 common shares at an exercise price of $10.42 per share and then sold 26,920 common shares at a weighted average price of $39.1079 per share, again ending with 0 common shares directly held. Following these transactions, she continues to hold stock options, including 3,211, 316, and 5,805 derivative securities with expiration dates between 2031 and 2034.